In a November 26 press release, Purdue Pharma L.P. announced that FDA has accepted its NDA for Targiniq ER for review. The investigational drug combines oxycodone with the opioid antagonist naloxone. It is currently marketed in 32 countries, including Canada, the UK, and Australia. Read the press release here.
Posted on December 5, 2013